Market Access News | pharmaphorum

News

NHS sets aside £340m for new Innovative Medicines Fund

NHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of money for a new Innovative Medicines Fund (IMF) that will provide early access to cutt

News

Novartis eyes New Year verdict from FDA on delayed Leqvio

Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date o

News

scientifically visualization of a coronavirus spike protein

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May.

News

Hard times at Ardelyx as FDA rejects kidney disease drug ten...

The FDA has taken a longer than usual look at Ardelyx's regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found i

News

Illustration of the thought processes in the brain

FDA gives speedy review to Bayer's Parkinson's stem cell the...

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinic

News

FDA okays Merck's would-be Prevnar rival Vaxneuvance

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot.

NHS sets aside £340m for new Innovative Medicines Fund

Novartis eyes New Year verdict from FDA on delayed Leqvio

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

Hard times at Ardelyx as FDA rejects kidney disease drug ten...

FDA gives speedy review to Bayer's Parkinson's stem cell the...

FDA okays Merck's would-be Prevnar rival Vaxneuvance

Datroway joins Trodelvy for frontline TNBC in the EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks